What is the standard prophylaxis approach for high-risk HSCT recipients to prevent fungal infections?

What is the standard prophylaxis approach for high-risk HSCT recipients to prevent fungal infections?

• A. Fluconazole or posaconazole prophylaxis (depending on risk)
• B. Nystatin prophylaxis
• C. Amphotericin B prophylaxis
• D. No prophylaxis

Answer: (A)

The key idea is that patients after HSCT face a high risk of invasive fungal infections due to prolonged neutropenia and immunosuppression, so antifungal prophylaxis is tailored to the level of risk. Fluconazole covers Candida species effectively and is suitable for lower or intermediate risk. For those at the greatest risk of mold infections (such as allogeneic HSCT recipients with GVHD risk or very prolonged neutropenia), a mold‑active agent like posaconazole is preferred because it also protects against Aspergillus and other molds. This combination—fluconazole for some patients and posaconazole for higher-risk patients—represents the standard approach to prevent fungal infections in high-risk HSCT recipients. Nystatin doesn’t cover systemic fungi, amphotericin B prophylaxis is too toxic for routine use, and withholding prophylaxis leaves patients vulnerable, so prophylaxis with either fluconazole or posaconazole according to risk is the best practice.

The key idea is that patients after HSCT face a high risk of invasive fungal infections due to prolonged neutropenia and immunosuppression, so antifungal prophylaxis is tailored to the level of risk. Fluconazole covers Candida species effectively and is suitable for lower or intermediate risk. For those at the greatest risk of mold infections (such as allogeneic HSCT recipients with GVHD risk or very prolonged neutropenia), a mold‑active agent like posaconazole is preferred because it also protects against Aspergillus and other molds. This combination—fluconazole for some patients and posaconazole for higher-risk patients—represents the standard approach to prevent fungal infections in high-risk HSCT recipients. Nystatin doesn’t cover systemic fungi, amphotericin B prophylaxis is too toxic for routine use, and withholding prophylaxis leaves patients vulnerable, so prophylaxis with either fluconazole or posaconazole according to risk is the best practice.